A treatment candidate from Regeneron (REGN) and Sanofi (SNY) in a new class of cholesterol-fighting drugs met its main target in a phase-two study. Alirocumab is an antibody that targets PCSK9, an enzyme that helps regulate the amount of cholesterol in the bloodstream. The trial follows recent positive study results from Amgen's (AMGN) own PCSK9 drug. Amgen rose 2.2% after Mon.'s 2.3% gain. Regeneron advanced 2.2%; Sanofi fell 0.7%.